Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Abramson JS, Palomba ML, Gordon LI, Lunning MA, et al. Blood 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854.

Read + Share

Amedeo Smart

Independent Medical Education

Abramson JS, Palomba ML, Gordon LI, Lunning MA, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854.
PMID: 37890149